Conclusion: The majority of the patients reported adverse events limited to grade 1 or 2. On the whole, the data presented herein confirm the findings of previous studies on the relative safety of everolimus, a targeted therapeutic agent, which differs from that of conventional chemotherapy, and highlight the potential adverse events associated with the therapeutic use of everolimus.
PubMed 34132370 ↗Rapamycin
Also known as Sirolimus
The short answer. There isn't much data on Rapamycin yet — 61 mentions, 11 with a clear outcome — so treat these numbers as anecdotal. It is most often used for longevity: 100% of 7 reports say that improved. It is well studied — 497 meta-analyses on PubMed.
From 61 mentions in total — the rest didn't say how it went and aren't counted.
What Rapamycin does, according to users
Of the people who reported each effect, the share who said it got better.
6 more with fewer than 3 reports
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 497 meta-analyses on PubMed ↗ · 1,245 randomized trials ↗
Conclusion: GD's complex pathophysiology involves multiple disruptions in insulin signaling, mitochondrial function, inflammation, and oxidative stress. Effective management requires early detection, preventive strategies, and international collaboration to standardize care and improve outcomes for mothers and babies.
PubMed 39519193 ↗Conclusion: Among patients undergoing DCB-only PCI, the risk of TLF was similar during 9-12 months of follow-up after PCB and SCB treatment. However, the MLD was larger favoring PCB over SCB on follow-up angiography.
PubMed 39044661 ↗Conclusion: Currently, there are no published RCTs of orbital lymphangioma treatments. Without these types of studies, conclusions cannot be drawn regarding the effectiveness of the medical and surgical treatment options for patients with orbital lymphangiomas. The presence of only case reports and case series on orbital lymphangiomas makes it clear that RCTs are needed to address the differences between these options and help guide treatment plans. Such trials would ideally compare outcomes between individuals randomized to one of the following treatment options: observation, sclerotherapy, systemic siro
PubMed 31094450 ↗2,389 human trials on ClinicalTrials.gov test Rapamycin — 1,292 completed, 197 recruiting now. See all on ClinicalTrials.gov ↗
- A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery · Complication of Renal Dialysis, End Stage Renal Disease · 2025
- Observatory to Assess the Yukon Choice PC & the Yukon Chrome PC Sirolimus Eluting Bioabsorbable Polymer Stents Systems · Coronaropathy · 2024
- Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) · Tumor, Tumor, Solid · 2024
What government agencies say
Official records from US, Canadian and EU regulators, each linked to its source.
Boxed warning (the FDA's strongest label warning): “IMMUNOSUPPRESSION, USE IS NOT RECOMMENDED IN LIVER OR LUNG TRANSPLANT PATIENTS Increased susceptibility to infection and the possible development of lymphoma and other malignancies may result from immunosuppression Increased susceptibility to infection and the possible development of lymphoma may…”
5 recalls of products named for Rapamycin. Most recent:
- 2024-05-29 · Class III: Failed Impurities/Degradation Specifications record ↗
- 2022-05-25 · Class III: Failed Dissolution Specifications: Sirolimus Oral Solution recalled due to lot RZ1598 exceeded the specification limit at the 14-month timepoint. record ↗
- 2021-09-29 · Class III: Failed Impurities/Degradation Specifications record ↗
Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗
13,365 adverse-event reports mention Rapamycin. Most often reported:
- Off label use · 2,055
- Drug ineffective · 1,116
- Product use in unapproved indication · 784
- Pyrexia · 524
- Diarrhoea · 514
- Pneumonia · 487
Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗
LiverTox rates Rapamycin C — a probable rare cause of liver injury (3–12 published cases). LiverTox entry ↗
NIH has funded 137 research projects with Rapamycin in the title, $138,138,622 in total (1992–2026). NIH RePORTER ↗
Plain-language guides from the US government: MedlinePlus: Sirolimus ↗
Dosage people report
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“I've noticed a 10% increase in HDL and some fatigue the day after taking more than 6mg.”
“A month after Rapamycin, I dropped 9 lbs from 230 to 220.”
“Rapamycin is used clinically to prevent organ rejection in transplant recipients. I would not recommend taking an immunosuppressant recreationally.”
“My skin looks great, my metabolic profile is great, blood pressure is great”
Rapamycin compared
Other options for longevity
Sources
- User reports: 61 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
- FDA drug label (DailyMed) ↗
- FDA adverse-event reports (FAERS) ↗
- FDA recalls ↗
- LiverTox (NIH) ↗
- MedlinePlus (NIH) ↗
- NIH RePORTER ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate